Drug
Tesamorelin clinical trials
Also written Egrifta and TH9507.
- studies test it
- 18
- open now
- 3
- in phase 3
- 2
- first study started
- 2002
Keep track of what changes. Save the tesamorelin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 10
- Phase 3
- 2
- Phase 4
- 2
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 11
Massachusetts General Hospital (6) · Theratechnologies (6) · University of California, San Diego (1) · University of Washington (1) · Hudson Biotech (1) · Johns Hopkins University (1) · Columbia University (1) · National Institute of Nursing Research (NINR) (1)
Studies
Open first, then newest update. How each study uses tesamorelin is read from its arms, and is right about nine times in ten.
Testing it · 18
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIVRecruitingPhase 2Massachusetts General HospitalNCT06554717Written as Tesamorelin
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)RecruitingPhase 2Hudson BiotechNCT07481734Written as Tesamorelin
- Tesamorelin to Improve Functional Outcomes After Peripheral Nerve InjuryRecruitingPhase 2Johns Hopkins UniversityNCT03150511Written as Tesamorelin 2 Milligrams (MG)
- Body Composition and Adipose Tissue in HIVTerminatedPhase 4Columbia UniversityNCT03226821Written as Tesamorelin
- Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected PersonsCompletedPhase 2University of California, San DiegoNCT02572323Written as Tesamorelin
- Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular RiskCompletedPhase 2Massachusetts General HospitalNCT03375788Written as Tesamorelin
- TH9507 Extension Study in Patients With HIV-Associated LipodystrophyCompletedPhase 3TheratechnologiesNCT00608023Written as Tesamorelin
- Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle WastingTerminatedPhase 2TheratechnologiesNCT01388920Written as Tesamorelin
- Tesamorelin Effects on Liver Fat and Histology in HIVCompletedNot applicableMassachusetts General HospitalNCT02196831Written as tesamorelin
- Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current InsomniaWithdrawnPhase 2National Institute of Nursing Research (NINR)NCT02931474Written as Tesamorelin
- Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®TerminatedPhase 4TheratechnologiesNCT01591902Written as Tesamorelin
- Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are ObeseCompletedPhase 2Massachusetts General HospitalNCT00675506Written as Growth hormone releasing hormone (GHRH) 1-44
- Effects of Growth Hormone Releasing Hormone in HIVCompletedNot applicableMassachusetts General HospitalNCT01263717Written as tesamorelin
- Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone AnalogueWithdrawnNot applicableMassachusetts General HospitalNCT01632592Written as Tesamorelin
- SMART: Somatotrophics, Memory, and Aging Research TrialCompletedPhase 2University of WashingtonNCT00257712Written as TH9507 human growth hormone releasing hormone (GHRH)
- Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive PatientsCompletedPhase 1TheratechnologiesNCT02012556Written as Tesamorelin
- TH9507 in Patients With HIV-Associated LipodystrophyCompletedPhase 3TheratechnologiesNCT00123253Written as TH9507
- Safety Study of TH9507 in Subjects With Stable, Type 2 DiabetesCompletedPhase 2TheratechnologiesNCT01264497Written as TH9507
Codes
What other systems call tesamorelin · ClinicalTrials.gg INT004590
- MeSH (NLM) C479538tesamorelinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) MQG94M5EEOTESAMORELINConfirmed FDA, NLM
- RxNorm 1044584One source FDA
- NCI Thesaurus C77425TesamorelinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C479538 | tesamorelin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | MQG94M5EEO | TESAMORELIN | Confirmed FDA, NLM |
| RxNorm | 1044584 | — | One source FDA |
| NCI Thesaurus | C77425 | Tesamorelin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.